749 related articles for article (PubMed ID: 8690909)
21. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
Chamuleau ME; Souwer Y; Van Ham SM; Zevenbergen A; Westers TM; Berkhof J; Meijer CJ; van de Loosdrecht AA; Ossenkoppele GJ
Cancer Res; 2004 Aug; 64(16):5546-50. PubMed ID: 15313888
[TBL] [Abstract][Full Text] [Related]
22. A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody.
Eastman S; Deftos M; DeRoos PC; Hsu DH; Teyton L; Braunstein NS; Hackett CJ; Rudensky A
Eur J Immunol; 1996 Feb; 26(2):385-93. PubMed ID: 8617308
[TBL] [Abstract][Full Text] [Related]
23. Presentation of abundant endogenous class II DR-restricted antigens by DM-negative B cell lines.
Kovats S; Whiteley PE; Concannon P; Rudensky AY; Blum JS
Eur J Immunol; 1997 Apr; 27(4):1014-21. PubMed ID: 9130658
[TBL] [Abstract][Full Text] [Related]
24. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel C; van Endert P; Koch N
J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
[TBL] [Abstract][Full Text] [Related]
25. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
26. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
27. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
Long EO; LaVaute T; Pinet V; Jaraquemada D
J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
[TBL] [Abstract][Full Text] [Related]
28. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing.
Bellemare-Pelletier A; Tremblay J; Beaulieu S; Boulassel MR; Routy JP; Massie B; Lapointe R; Thibodeau J
J Leukoc Biol; 2005 Jul; 78(1):95-105. PubMed ID: 15817706
[TBL] [Abstract][Full Text] [Related]
29. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
30. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM.
Peterson M; Sant AJ
J Immunol; 1998 Sep; 161(6):2961-7. PubMed ID: 9743359
[TBL] [Abstract][Full Text] [Related]
31. Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes.
Brooks AG; Campbell PL; Reynolds P; Gautam AM; McCluskey J
J Immunol; 1994 Dec; 153(12):5382-92. PubMed ID: 7989744
[TBL] [Abstract][Full Text] [Related]
32. DM and DO shape the repertoire of peptide-MHC-class-II complexes.
Karlsson L
Curr Opin Immunol; 2005 Feb; 17(1):65-70. PubMed ID: 15653313
[TBL] [Abstract][Full Text] [Related]
33. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens.
Cheng PC; Steele CR; Gu L; Song W; Pierce SK
J Immunol; 1999 Jun; 162(12):7171-80. PubMed ID: 10358163
[TBL] [Abstract][Full Text] [Related]
34. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain.
Simonsen A; Pedersen KW; Nordeng TW; von der Lippe A; Stang E; Long EO; Bakke O
J Immunol; 1999 Sep; 163(5):2540-8. PubMed ID: 10452991
[TBL] [Abstract][Full Text] [Related]
35. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
36. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
37. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
38. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain.
Busch R; Vturina IY; Drexler J; Momburg F; Hämmerling GJ
Eur J Immunol; 1995 Jan; 25(1):48-53. PubMed ID: 7843252
[TBL] [Abstract][Full Text] [Related]
39. Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia.
Veenstra H; Jacobs P; Dowdle EB
Cell Immunol; 1996 Jul; 171(1):68-73. PubMed ID: 8660839
[TBL] [Abstract][Full Text] [Related]
40. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules.
Morris P; Shaman J; Attaya M; Amaya M; Goodman S; Bergman C; Monaco JJ; Mellins E
Nature; 1994 Apr; 368(6471):551-4. PubMed ID: 8139689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
